top of page

ALLOSTERIC MODULATION

We’re a talented group of scientists and entrepreneurs with a groundbreaking ability to 'see' and characterize new functional allosteric binding sites on proteins for drug development.

 

Our proprietary hydrogen-deuterium exchange LC-MS/MS (fastHDX™) can take soluble proteins of interest and map out remote (allosteric) binding sites capable of actually modulating the active (orthosteric) site and rapidly deliver early allosteric hits against molecular targets with high target selectivity.

binding graphic.png
fastHDX graphic.png

OUR TECHNOLOGY

Our proprietary fastHD approach, based on 50 years experience in high speed liquid exchange, enables us to see quickly the effects of low affinity allosteric binding typical of the early hits generated in fragment-based drug design programmes. 

Anchor 3
Anchor 1

EXECUTIVE TEAM

JJ Phillips_edited_edited.png

DR LINDSAY COLE

Director & CSO

  • LinkedIn

DR JOHN NORMANTON

Director & CEO

  • LinkedIn

DR JJ PHILLIPS

Director & Scientific Consultant

  • LinkedIn
Gerry Ronan_edited_edited_edited.png

DR TIM FLANAGAN

Chairman

  • LinkedIn

DR GERRY RONAN

Non-Executive Director

  • LinkedIn

ADDITIONAL BOARD MEMBERS

GET IN TOUCH

Allosterica Limited

+44 7831 800 683

Thanks for submitting!

Anchor 2
Anchor 4
bottom of page